

Dr. Henning Gädeke
c/o Dr. Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

5 May 2026

Letter of endorsement

Dear Sir/Madam,

On behalf of Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Arrondissement 4 Rue 2 D1, Pole Urbain de Diamniadio, and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

TB is still a worldwide health concern with 10.8 million new cases and 1.3 million deaths attributable to TB in 2023. There is an urgent global need to develop new TB vaccines that are more effective than the only licensed vaccine, live attenuated *Mycobacterium bovis* Bacille Calmette Guérin (BCG). IRESSEF recognizes the critical importance of further developing the Global TB Vaccine R&D roadmap and is committed to the ambition of reducing the global burden of Tuberculosis (TB).

Therefore, IRESSEF fully supports this comprehensive EDCTP3-2025-01-TB-01-two-stage application, entitled *Evaluating a Multi-Valent Aerosol Booster TB Vaccine for Adolescents and Young Adults in Diverse African Settings: T5 TBVAC*, involving a consortium led by the University of Oxford (UOXF) and, comprising 4 partners, the University of Oxford (UOXF), Uganda National Health Research Organisation (UVRI), *Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation* (IRESSEF) and Tuberculosis Vaccine Initiative (TBVI).

IRESSEF will participate in six of the seven Work Packages (WP2 through WP7) and will lead WP4.

IRESSEF will provide fully air-conditioned, adequately equipped office and laboratory spaces, as well as meeting rooms, ready for immediate use and optimized for both administrative and capacity-building activities. Additionally, the project will benefit from institutional support through the commitment and contributions of its Administration, Finance, Data Management and IT, Maintenance and Metrology, Quality Assurance, and Biosecurity platforms, all critical for the project's smooth implementation. This in-kind

contribution is valued at approximately €59,280 in direct costs (including €3,648 for WP2, €36,480 for WP3, €12,160 for WP4, €2,432 for WP5, and €4,560 for WP7), plus €14,820 in indirect costs, for a total of €74,100, representing a significant institutional investment in the project.

We confirm the following:

- We are committed to the principles of Open Science, FAIR data access, gender equality and Good Clinical Practice required to take part in this consortium.
- We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
- We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.

Yours faithfully,



May 5th, 2026,

Prof. Souleymane Mboup

IRESSEF CEO